All Outputs (126)

Hydroxyacid oxidase 1, a glutamine metabolism-associated protein, predicts poor patient outcome in luminal breast cancer (2024)
Journal Article
Erkan, B., MacIntyre, S., Brown, C., Fakroun, A., Lashen, A. G., Mongan, N. P., Ellis, I. O., Rakha, E. A., & Green, A. R. (2024). Hydroxyacid oxidase 1, a glutamine metabolism-associated protein, predicts poor patient outcome in luminal breast cancer. International Journal of Molecular Sciences, 25(21), Article 11572. https://doi.org/10.3390/ijms252111572

Background
Breast cancer (BC), which remains the most prevalent malignancy among women, is characterised by significant heterogeneity across its molecular subtypes. Oestrogen Receptor-positive (ER+) (luminal) BC represents approximately 75% cases an... Read More about Hydroxyacid oxidase 1, a glutamine metabolism-associated protein, predicts poor patient outcome in luminal breast cancer.

Geometric characteristics of stromal collagen fibres in breast cancer using differential interference contrast microscopy (2024)
Journal Article
Ghannam, S. F., Rutland, C. S., Allegrucci, C., Mather, M. L., Alsaleem, M., Bateman‐Price, T. D., Patke, R., Ball, G., Mongan, N. P., & Rakha, E. (2024). Geometric characteristics of stromal collagen fibres in breast cancer using differential interference contrast microscopy. Journal of Microscopy, https://doi.org/10.1111/jmi.13361

Breast cancer (BC) is characterised by a high level of heterogeneity, which is influenced by the interaction of neoplastic cells with the tumour microenvironment. The diagnostic and prognostic role of the tumour stroma in BC remains to be defined. Di... Read More about Geometric characteristics of stromal collagen fibres in breast cancer using differential interference contrast microscopy.

Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer (2024)
Journal Article
Kariri, Y. A., Alsaleem, M., Alhatlani, B. Y., Al-Kawaz, A., Mongan, N. P., Green, A. R., & Rakha, E. (in press). Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer. Pathology,

The Conflicting Prognostic Role of the Stroma–Tumor Ratio in Breast Cancer Molecular Subtypes (2024)
Journal Article
Ghannam, S. F., Makhlouf, S., Alsaleem, M., Rutland, C. S., Allegrucci, C., Mongan, N. P., & Rakha, E. (2024). The Conflicting Prognostic Role of the Stroma–Tumor Ratio in Breast Cancer Molecular Subtypes. Modern Pathology, 37(12), Article 100607. https://doi.org/10.1016/j.modpat.2024.100607

The tumor microenvironment plays a key role in tumor progression. The proportion of the stroma-to-tumor cells (stroma-tumor ratio [STR]) has a variable prognostic significance in breast cancer (BC) molecular classes. In this study, we evaluated the m... Read More about The Conflicting Prognostic Role of the Stroma–Tumor Ratio in Breast Cancer Molecular Subtypes.

Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer (2024)
Journal Article
Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2024). Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer. Pathobiology, https://doi.org/10.1159/000540790

Introduction: Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined.... Read More about Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer.

The role of the ALKBH5 RNA demethylase in invasive breast cancer (2024)
Journal Article
Woodcock, C. L., Alsaleem, M., Toss, M. S., Lothion-Roy, J., Harris, A. E., Jeyapalan, J. N., Blatt, N., Rizvanov, A. A., Miftakhova, R. R., Kariri, Y. A., Madhusudan, S., Green, A. R., Rutland, C. S., Fray, R. G., Rakha, E. A., & Mongan, N. P. (2024). The role of the ALKBH5 RNA demethylase in invasive breast cancer. Discover Oncology, 15(1), Article 343. https://doi.org/10.1007/s12672-024-01205-8

Background: N6-methyladenosine (m6A) is the most common internal RNA modification and is involved in regulation of RNA and protein expression. AlkB family member 5 (ALKBH5) is a m6A demethylase. Given the important role of m6A in biological mechanism... Read More about The role of the ALKBH5 RNA demethylase in invasive breast cancer.

Epitranscriptomic mechanisms of androgen signalling and prostate cancer (2024)
Journal Article
Patke, R., Harris, A. E., Woodcock, C. L., Thompson, R., Santos, R., Kumari, A., Allegrucci, C., Archer, N., Gudas, L. J., Robinson, B. D., Persson, J. L., Fray, R., Jeyapalan, J., Rutland, C. S., Rakha, E., Madhusudan, S., Emes, R. D., Muyangwa-Semenova, M., Alsaleem, M., de Brot, S., …Lothion-Roy, J. (2024). Epitranscriptomic mechanisms of androgen signalling and prostate cancer. Neoplasia, 56, Article 101032. https://doi.org/10.1016/j.neo.2024.101032

Prostate cancer (PCa) is the second most common cancer diagnosed in men. While radical prostatectomy and radiotherapy are often successful in treating localised disease, post-treatment recurrence is common. As the androgen receptor (AR) and androgen... Read More about Epitranscriptomic mechanisms of androgen signalling and prostate cancer.

The characteristics and prognostic significance of histone H1 expression in breast cancer (2024)
Journal Article
Lashen, A. G., Almalki, N., Toss, M., Mirza, S., Malki, M. I., Rutland, C. S., Jeyapalan, J. N., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. A. (2024). The characteristics and prognostic significance of histone H1 expression in breast cancer. Pathology, 56(6), 826-833. https://doi.org/10.1016/j.pathol.2024.03.012

Histone H1 (H.H1) is involved in chromatin organisation and gene regulation and is overexpressed in many malignant tumours, including breast cancer (BC). This study proposed and evaluated the prognostic role of H.H1 expression in BC.

H.H1 mRNA exp... Read More about The characteristics and prognostic significance of histone H1 expression in breast cancer.

Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma (2024)
Journal Article
de Brot, S., Cobb, J., Alibhai, A. A., Jackson-Oxley, J., Haque, M., Patke, R., …Rutland, C. S. (2024). Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma. Cancers, 16(10), Article 1945. https://doi.org/10.3390/cancers16101945

Osteosarcoma (OSA) is the most common type of primary bone malignancy in people and dogs. Our previous molecular comparisons of canine OSA against healthy bone resulted in the identification of differentially expressed protein-expressing genes (forkh... Read More about Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma.

NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2 (2024)
Journal Article
Cardenas, R. P., Zyoud, A., McIntyre, A., Alberio, R., Mongan, N. P., & Allegrucci, C. (2024). NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2. Stem Cell Research and Therapy, 15(1), Article 128. https://doi.org/10.1186/s13287-024-03724-1

Background
Testicular germ cell tumours (TGCTs) represent a clinical challenge; they are most prevalent in young individuals and are triggered by molecular mechanisms that are not fully understood. The origin of TGCTs can be traced back to primordia... Read More about NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.

Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers (2024)
Journal Article
Lashen, A., Alqahtani, S., Shoqafi, A., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2024). Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers. International Journal of Molecular Sciences, 25(9), Article 5053. https://doi.org/10.3390/ijms25095053

Cyclin-dependent kinase 2 (CDK2) is a key cell cycle regulator, with essential roles during G1/S transition. The clinicopathological significance of CDK2 in ductal carcinomas in situ (DCIS) and early-stage invasive breast cancers (BCs) remains largel... Read More about Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers (2024)
Journal Article
Lashen, A., Algethami, M., Alqahtani, S., Shoqafi, A., Sheha, A., Jeyapalan, J. N., …Madhusudan, S. (2024). The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 25(7), Article 4060. https://doi.org/10.3390/ijms25074060

Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylated retinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging t... Read More about The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

Modulation of the pre-metastatic bone niche: molecular changes mediated by bone-homing prostate cancer extracellular vesicles (2024)
Journal Article
Brown, T. J., Rutland, C. S., Rutland, C. S., Choi, K. K., Tse, F., Pfeffers, M. J., …James, V. (2024). Modulation of the pre-metastatic bone niche: molecular changes mediated by bone-homing prostate cancer extracellular vesicles. Frontiers in Cell and Developmental Biology, 12, Article 1354606. https://doi.org/10.3389/fcell.2024.1354606

Prostate cancer (PCa) is a leading male malignancy worldwide, often progressing to bone metastasis, with limited curative options. Extracellular vesicles (EVs) have emerged as key players in cancer communication and metastasis, promoting the formatio... Read More about Modulation of the pre-metastatic bone niche: molecular changes mediated by bone-homing prostate cancer extracellular vesicles.

Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance (2023)
Journal Article
Makhlouf, S., Quinn, C., Toss, M., Alsaleem, M., Atallah, N. M., Ibrahim, A., …Rakha, E. A. (2024). Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance. European Journal of Cancer, 197, Article 113473. https://doi.org/10.1016/j.ejca.2023.113473

Background

Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform... Read More about Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance.

Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression (2023)
Journal Article
Atallah, N. M., Haque, M., Quinn, C., Toss, M. S., Makhlouf, S., Ibrahim, A., …Rakha, E. (2023). Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. European Journal of Cancer, 195, Article 113371. https://doi.org/10.1016/j.ejca.2023.113371

Background: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of... Read More about Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level (2023)
Journal Article
Atallah, N. M., Alsaleem, M., Toss, M. S., Mongan, N. P., & Rakha, E. (2023). Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level. British Journal of Cancer, https://doi.org/10.1038/s41416-023-02426-4

Background: Increasing data indicate that HER2-positive (HER2 +) breast cancer (BC) subtypes exhibit differential responses to targeted anti-HER2 therapy. This study aims to investigate these differences and the potential underlying molecular mechani... Read More about Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.

The clinical and biological significance of estrogen receptor-low positive breast cancer (2023)
Journal Article
Makhlouf, S., Althobi, M., Toss, M., Muftah, A. A., Mongan, N. P., Lee, A. H. S., …Rakha, E. A. (2023). The clinical and biological significance of estrogen receptor-low positive breast cancer. Modern Pathology, 36(10), Article 100284. https://doi.org/10.1016/j.modpat.2023.100284

Estrogen Receptor (ER) status in breast cancer (BC) is determined using immunohistochemistry (IHC) with nuclear expression in ≥1% of cells defined as ER-positive. BC with 1-9% expression (ER-low positive), is a clinically and biologically unique subg... Read More about The clinical and biological significance of estrogen receptor-low positive breast cancer.

Encapsulated papillary carcinoma of the breast: does it have a native basement membrane? (2023)
Journal Article
Ghannam, S. F., Rutland, C. S., Allegrucci, C., Mongan, N. P., & Rakha, E. (2023). Encapsulated papillary carcinoma of the breast: does it have a native basement membrane?. Histopathology, 83(3), 376-393. https://doi.org/10.1111/his.14939

Background
Encapsulated papillary carcinoma (EPC) is surrounded by a thick fibrous capsule-like structure, which is interpreted as a thickened basement membrane (BM). This study aimed to describe the geometric characteristics of the EPC capsule and... Read More about Encapsulated papillary carcinoma of the breast: does it have a native basement membrane?.

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer (2023)
Journal Article
Lashen, A. G., Toss, M. S., Wootton, L., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. (2023). Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer. Histopathology, 83(3), 414-425. https://doi.org/10.1111/his.14960

Background: Polo-like kinase-1 (PLK1) plays a crucial role in cell cycle progression,and it is considered a potential therapeutic target in many cancers. Although the role of PLK1 is well established in triple negative breast cancer (TNBC) as an onco... Read More about Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.

Targeting DNA damage repair precision medicine strategies in cancer (2023)
Journal Article
Brownlie, J., Kulkarni, S., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2023). Targeting DNA damage repair precision medicine strategies in cancer. Current Opinion in Pharmacology, 70, Article 102381. https://doi.org/10.1016/j.coph.2023.102381

DNA repair targeted therapeutics is a promising precision medicine strategy in cancer. The development and clinical use of PARP inhibitors has transformed lives for many patients with BRCA germline deficient breast and ovarian cancer as well as plati... Read More about Targeting DNA damage repair precision medicine strategies in cancer.